雷贝拉唑联合莫沙必利治疗反流性食管炎的临床效果及有效率影响分析  

Effect of Rabeprazole Combined with Mosapride on Reflux Esophagitis and Its Effective Rate

作　　者：蒋晶超 邱玉艳[1] JIANG Jingchao;QIU Yuyan(Harbin 242 Hospital,Harbin 150066,China)

机构地区：[1]哈尔滨二四二医院,哈尔滨150066

出　　处：《航空航天医学杂志》2021年第1期6-7,共2页Journal of Aerospace medicine

摘　　要：目的探讨反流性食管炎采用雷贝拉唑与莫沙比利联用应用的治疗价值。方法选取反流性食管炎100例,均为2018年6月-2019年6月收治,随机分组,就雷贝拉唑单用(对照组,n=50)与加用莫沙比利(观察组,n=50)治疗效果对比。结果观察组总有效率高于对照组(P<0.05)。两组治疗后,典型症状评分、炎性因子均低于对照组(P<0.05)。两组不良反应率无统计学差异(P<0.05)。结论反流性食管炎采用雷贝拉唑联用莫沙比利治疗,可显著提高总有效率,改善临床症状,降低血清炎性因子水平,且具较高安全性。Objective To explore the value of combination of rabeprazole and mosapride in reflux esophagitis. Methods 100 cases of reflux esophagitis were selected. All of them were treated in our hospital from June 2018 to June 2019. They were randomly divided into two groups: rabeprazole alone(control group, n=50) and moxabi Contrast of the treatment effect of Lili(observation group, n=50). Results The total effective rate in the observation group was higher than that in the control group(P<0.05). After treatment in both groups, the typical symptom score and inflammatory factors were lower than those in the control group(P<0.05). There were no significant differences in adverse reaction rates between the two groups(P<0.05). Conclusions Reflux esophagitis treated with rabeprazole and moxapride can significantly improve the total effective rate, improve clinical symptoms, reduce serum inflammatory factor levels, and has high safety.

关 键 词：反流性食管炎 雷贝拉唑 莫沙必利 症状评分 炎性因子 

分 类 号：R571[医药卫生—消化系统]